Table 2.
Tumour reduction in PFS prognostic subgroups in the vemurafenib monotherapy pooled cohort and the cobimetinib plus vemurafenib pooled cohort
| Prognostic subgroup | Max%SLD in pooled V cohort | Max%SLD in pooled C + V cohort | ||||
|---|---|---|---|---|---|---|
| n | Median | IQR | n | Median | IQR | |
| All pooled patients with tumour reductiona | 627 | –53.3 | –73.6 to –33.8 | 282 | –74.4 | –94.1 to –55.2 |
| LDH level normal and liver metastases absent | 266 | –56.8 | –88.6 to –38.2 | 117 | –75.0 | –100 to –56.3 |
| LDH level normal and liver metastases present | 87 | –61.1 | –77.2 to –43.4 | 35 | –75.0 | –90.4 to –51.7 |
| LDH level elevated and ECOG PS = 0 | 121 | –47.5 | –69.1 to –30.3 | 85 | –77.0 | –91.0 to –61.8 |
| LDH elevated and ECOG PS > 0 | 148 | –45.7 | –59.9 to –27.7 | 39 | –60.0 | –75.4 to –46.2 |
C + V cobimetinib plus vemurafenib, ECOG PS Eastern Cooperative Oncology Group performance status, IQR interquartile range, LDH lactate dehydrogenase, Max%SLD maximum percentage change in the sum of longest diameters, V vemurafenib monotherapy
aIncludes only patients with negative Max%SLD of target lesion